Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 103 entries
Sorted by: Best Match Show Resources per page
Patient-specific meta-analysis for risk assessment using multivariate proportional hazards regression.

Journal of applied statistics

Crager MR, Tang G.
PMID: 26664111
J Appl Stat. 2014;41(12):2676-2695. doi: 10.1080/02664763.2014.925102. Epub 2014 Jun 09.

We propose a method for assessing an individual patient's risk of a future clinical event using clinical trial or cohort data and Cox proportional hazards regression, combining the information from several studies using meta-analysis techniques. The method combines patient-specific...

Cite
Crager MR, Tang G. Patient-specific meta-analysis for risk assessment using multivariate proportional hazards regression. J Appl Stat. 2014;41(12):2676-2695doi: 10.1080/02664763.2014.925102.
Crager, M. R., & Tang, G. (2014). Patient-specific meta-analysis for risk assessment using multivariate proportional hazards regression. Journal of applied statistics, 41(12), 2676-2695. https://doi.org/10.1080/02664763.2014.925102
Crager, Michael R, and Tang, Gong. "Patient-specific meta-analysis for risk assessment using multivariate proportional hazards regression." Journal of applied statistics vol. 41,12 (2014): 2676-2695. doi: https://doi.org/10.1080/02664763.2014.925102
Crager MR, Tang G. Patient-specific meta-analysis for risk assessment using multivariate proportional hazards regression. J Appl Stat. 2014;41(12):2676-2695. doi: 10.1080/02664763.2014.925102. Epub 2014 Jun 09. PMID: 26664111; PMCID: PMC4673004.
Copy Download .nbib Format: NLM
Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials.

Current colorectal cancer reports

George TJ, Allegra CJ, Yothers G.
PMID: 26321890
Curr Colorectal Cancer Rep. 2015;11(5):275-280. doi: 10.1007/s11888-015-0285-2.

The conduct of clinical trials in colorectal cancer has historically relied upon endpoints such as disease-free (DFS) or overall survival (OS). While ideal, these endpoints require long-term follow-up, thus contributing to a slow pace of scientific progress in clinical...

Cite
George TJ, Allegra CJ, Yothers G. Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials. Curr Colorectal Cancer Rep. 2015;11(5):275-280doi: 10.1007/s11888-015-0285-2.
George, T. J., Allegra, C. J., & Yothers, G. (2015). Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials. Current colorectal cancer reports, 11(5), 275-280. https://doi.org/10.1007/s11888-015-0285-2
George, Thomas J, et al. "Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials." Current colorectal cancer reports vol. 11,5 (2015): 275-280. doi: https://doi.org/10.1007/s11888-015-0285-2
George TJ, Allegra CJ, Yothers G. Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials. Curr Colorectal Cancer Rep. 2015;11(5):275-280. doi: 10.1007/s11888-015-0285-2. PMID: 26321890; PMCID: PMC4550644.
Copy Download .nbib Format: NLM
Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients.

Clinical colorectal cancer

Margalit O, Boursi B, Rakez M, Thierry A, Yothers G, Wolmark N, Haller DG, Schmoll HJ, Shi Q, Shacham-Shmueli E, de Gramont A.
PMID: 33775561
Clin Colorectal Cancer. 2021 Jun;20(2):130-136. doi: 10.1016/j.clcc.2021.02.001. Epub 2021 Feb 19.

BACKGROUND: The International Duration Evaluation of Adjuvant Chemotherapy (IDEA) pooled analysis compared 3 to 6 months of adjuvant chemotherapy for stage III colon cancer. Patients were classified into low risk and high risk, suggesting low-risk patients may be offered...

Cite
Margalit O, Boursi B, Rakez M, et al. Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients. Clin Colorectal Cancer. 2021;20(2):130-136doi: 10.1016/j.clcc.2021.02.001.
Margalit, O., Boursi, B., Rakez, M., Thierry, A., Yothers, G., Wolmark, N., Haller, D. G., Schmoll, H. J., Shi, Q., Shacham-Shmueli, E., & de Gramont, A. (2021). Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients. Clinical colorectal cancer, 20(2), 130-136. https://doi.org/10.1016/j.clcc.2021.02.001
Margalit, Ofer, et al. "Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients." Clinical colorectal cancer vol. 20,2 (2021): 130-136. doi: https://doi.org/10.1016/j.clcc.2021.02.001
Margalit O, Boursi B, Rakez M, Thierry A, Yothers G, Wolmark N, Haller DG, Schmoll HJ, Shi Q, Shacham-Shmueli E, de Gramont A. Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients. Clin Colorectal Cancer. 2021 Jun;20(2):130-136. doi: 10.1016/j.clcc.2021.02.001. Epub 2021 Feb 19. PMID: 33775561.
Copy Download .nbib Format: NLM
A robust permutation test for the concordance correlation coefficient.

Pharmaceutical statistics

Hutson AD, Yu H.
PMID: 33599032
Pharm Stat. 2021 Jul;20(4):696-709. doi: 10.1002/pst.2101. Epub 2021 Feb 17.

In this work, we developed a robust permutation test for the concordance correlation coefficient (ρ

Cite
Hutson AD, Yu H. A robust permutation test for the concordance correlation coefficient. Pharm Stat. 2021;20(4):696-709doi: 10.1002/pst.2101.
Hutson, A. D., & Yu, H. (2021). A robust permutation test for the concordance correlation coefficient. Pharmaceutical statistics, 20(4), 696-709. https://doi.org/10.1002/pst.2101
Hutson, Alan D, and Yu, Han. "A robust permutation test for the concordance correlation coefficient." Pharmaceutical statistics vol. 20,4 (2021): 696-709. doi: https://doi.org/10.1002/pst.2101
Hutson AD, Yu H. A robust permutation test for the concordance correlation coefficient. Pharm Stat. 2021 Jul;20(4):696-709. doi: 10.1002/pst.2101. Epub 2021 Feb 17. PMID: 33599032; PMCID: PMC8359348.
Copy Download .nbib Format: NLM
A robust permutation test for the concordance correlation coefficient.

Pharmaceutical statistics

Hutson AD, Yu H.
PMID: 33599032
Pharm Stat. 2021 Jul;20(4):696-709. doi: 10.1002/pst.2101. Epub 2021 Feb 17.

In this work, we developed a robust permutation test for the concordance correlation coefficient (ρ

Cite
Hutson AD, Yu H. A robust permutation test for the concordance correlation coefficient. Pharm Stat. 2021;20(4):696-709doi: 10.1002/pst.2101.
Hutson, A. D., & Yu, H. (2021). A robust permutation test for the concordance correlation coefficient. Pharmaceutical statistics, 20(4), 696-709. https://doi.org/10.1002/pst.2101
Hutson, Alan D, and Yu, Han. "A robust permutation test for the concordance correlation coefficient." Pharmaceutical statistics vol. 20,4 (2021): 696-709. doi: https://doi.org/10.1002/pst.2101
Hutson AD, Yu H. A robust permutation test for the concordance correlation coefficient. Pharm Stat. 2021 Jul;20(4):696-709. doi: 10.1002/pst.2101. Epub 2021 Feb 17. PMID: 33599032; PMCID: PMC8359348.
Copy Download .nbib Format: NLM
Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126.

International journal of radiation oncology, biology, physics

Hall WA, Deshmukh S, Bruner DW, Michalski JM, Purdy JA, Bosch W, Bahary JP, Patel MP, Parliament MB, Lock MI, Lau HY, Souhami L, Fisher SA, Kwok Y, Seider MJ, Vigneault E, Rosenthal SA, Gustafson GS, Gay HA, Pugh SL, Sandler HM, Movsas B.
PMID: 34919884
Int J Radiat Oncol Biol Phys. 2022 Jan 01;112(1):83-92. doi: 10.1016/j.ijrobp.2021.07.004.

PURPOSE: External beam radiation therapy (EBRT) dose escalation has been tested in multiple prospective trials. However, the impact on patient reported outcomes (PROs) associated with higher doses of EBRT remain poorly understood. We sought to assess the differences in...

Cite
Hall WA, Deshmukh S, Bruner DW, et al. Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126. Int J Radiat Oncol Biol Phys. 2022;112(1):83-92doi: 10.1016/j.ijrobp.2021.07.004.
Hall, W. A., Deshmukh, S., Bruner, D. W., Michalski, J. M., Purdy, J. A., Bosch, W., Bahary, J. P., Patel, M. P., Parliament, M. B., Lock, M. I., Lau, H. Y., Souhami, L., Fisher, S. A., Kwok, Y., Seider, M. J., Vigneault, E., Rosenthal, S. A., Gustafson, G. S., Gay, H. A., Pugh, S. L., Sandler, H. M., & Movsas, B. (2022). Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126. International journal of radiation oncology, biology, physics, 112(1), 83-92. https://doi.org/10.1016/j.ijrobp.2021.07.004
Hall, William A, et al. "Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126." International journal of radiation oncology, biology, physics vol. 112,1 (2022): 83-92. doi: https://doi.org/10.1016/j.ijrobp.2021.07.004
Hall WA, Deshmukh S, Bruner DW, Michalski JM, Purdy JA, Bosch W, Bahary JP, Patel MP, Parliament MB, Lock MI, Lau HY, Souhami L, Fisher SA, Kwok Y, Seider MJ, Vigneault E, Rosenthal SA, Gustafson GS, Gay HA, Pugh SL, Sandler HM, Movsas B. Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126. Int J Radiat Oncol Biol Phys. 2022 Jan 01;112(1):83-92. doi: 10.1016/j.ijrobp.2021.07.004. PMID: 34919884.
Copy Download .nbib Format: NLM
Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study.

Applied immunohistochemistry & molecular morphology : AIMM

Grushko TA, Filiaci VL, Montag AG, Apushkin M, Gomez MJ, Monovich L, Ramirez NC, Schwab C, Kesterson JP, Seward SM, Method MW, Olopade OI, Fleming GF, Birrer MJ.
PMID: 34224438
Appl Immunohistochem Mol Morphol. 2022 Jan 01;30(1):27-35. doi: 10.1097/PAI.0000000000000949.

We performed a pilot study in anticipation of using long-aged precut formalin-fixed paraffin-embedded tissue sections stored in real-world conditions for translational biomarker studies of topoisomerase 2A (TOP2A), Ki67, and human epidermal growth factor receptor 2 (HER2) in endometrial cancer....

Cite
Grushko TA, Filiaci VL, Montag AG, et al. Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study. Appl Immunohistochem Mol Morphol. 2022;30(1):27-35doi: 10.1097/PAI.0000000000000949.
Grushko, T. A., Filiaci, V. L., Montag, A. G., Apushkin, M., Gomez, M. J., Monovich, L., Ramirez, N. C., Schwab, C., Kesterson, J. P., Seward, S. M., Method, M. W., Olopade, O. I., Fleming, G. F., & Birrer, M. J. (2022). Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study. Applied immunohistochemistry & molecular morphology : AIMM, 30(1), 27-35. https://doi.org/10.1097/PAI.0000000000000949
Grushko, Tatyana A, et al. "Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study." Applied immunohistochemistry & molecular morphology : AIMM vol. 30,1 (2022): 27-35. doi: https://doi.org/10.1097/PAI.0000000000000949
Grushko TA, Filiaci VL, Montag AG, Apushkin M, Gomez MJ, Monovich L, Ramirez NC, Schwab C, Kesterson JP, Seward SM, Method MW, Olopade OI, Fleming GF, Birrer MJ. Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study. Appl Immunohistochem Mol Morphol. 2022 Jan 01;30(1):27-35. doi: 10.1097/PAI.0000000000000949. PMID: 34224438; PMCID: PMC8664981.
Copy Download .nbib Format: NLM
Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522.

Head & neck

Bigelow EO, Harris J, Fakhry C, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Frank SJ, Nair SG, Bahig H, Ridge JA, Caudell J, Donaldson C, Clifford BT, Shenouda G, Birrer MJ, Chen Y, Le QT.
PMID: 34729846
Head Neck. 2021 Nov 03; doi: 10.1002/hed.26915. Epub 2021 Nov 03.

BACKGROUND: No risk-stratification strategies exist for patients with recurrent oropharyngeal cancer (OPC).METHODS: Retrospective analysis using data from prospective NRG Oncology clinical trials RTOG 0129 and 0522. Eligibility criteria included known p16 status and smoking history, and locoregional/distant recurrence. Overall...

Cite
Bigelow EO, Harris J, Fakhry C, et al. Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. Head Neck. 2021;doi: 10.1002/hed.26915.
Bigelow, E. O., Harris, J., Fakhry, C., Gillison, M. L., Nguyen-Tân, P. F., Rosenthal, D. I., Frank, S. J., Nair, S. G., Bahig, H., Ridge, J. A., Caudell, J., Donaldson, C., Clifford, B. T., Shenouda, G., Birrer, M. J., Chen, Y., & Le, Q. T. (2021). Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. Head & neck, . https://doi.org/10.1002/hed.26915
Bigelow, Elaine O, et al. "Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522." Head & neck vol. (2021). doi: https://doi.org/10.1002/hed.26915
Bigelow EO, Harris J, Fakhry C, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Frank SJ, Nair SG, Bahig H, Ridge JA, Caudell J, Donaldson C, Clifford BT, Shenouda G, Birrer MJ, Chen Y, Le QT. Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. Head Neck. 2021 Nov 03; doi: 10.1002/hed.26915. Epub 2021 Nov 03. PMID: 34729846.
Copy Download .nbib Format: NLM
NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer.

Cancers

Bauman JE, Harris J, Uppaluri R, Yao M, Ferris RL, Chen J, Jordan RC, Joshi NP, Jujjuvaparu S, Blakaj DM, Henson C, Sheqwara J, Mell LK, Sen N, Clump DA, Garg MK, Yilmaz E, Torres-Saavedra P, Le QT.
PMID: 34207599
Cancers (Basel). 2021 Jun 09;13(12). doi: 10.3390/cancers13122882.

The anti-PD1 monoclonal antibody pembrolizumab improves survival in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Patients with locoregional, pathologically high-risk HNSCC recur frequently despite adjuvant cisplatin-radiation therapy (CRT). Targeting PD1 may reverse immunosuppression induced by HNSCC and CRT....

Cite
Bauman JE, Harris J, Uppaluri R, et al. NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. Cancers (Basel). 2021;13(12)doi: 10.3390/cancers13122882.
Bauman, J. E., Harris, J., Uppaluri, R., Yao, M., Ferris, R. L., Chen, J., Jordan, R. C., Joshi, N. P., Jujjuvaparu, S., Blakaj, D. M., Henson, C., Sheqwara, J., Mell, L. K., Sen, N., Clump, D. A., Garg, M. K., Yilmaz, E., Torres-Saavedra, P., & Le, Q. T. (2021). NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. Cancers, 13(12), . https://doi.org/10.3390/cancers13122882
Bauman, Julie E, et al. "NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer." Cancers vol. 13,12 (2021). doi: https://doi.org/10.3390/cancers13122882
Bauman JE, Harris J, Uppaluri R, Yao M, Ferris RL, Chen J, Jordan RC, Joshi NP, Jujjuvaparu S, Blakaj DM, Henson C, Sheqwara J, Mell LK, Sen N, Clump DA, Garg MK, Yilmaz E, Torres-Saavedra P, Le QT. NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. Cancers (Basel). 2021 Jun 09;13(12). doi: 10.3390/cancers13122882. PMID: 34207599; PMCID: PMC8230356.
Copy Download .nbib Format: NLM
Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522.

Head & neck

Bigelow EO, Harris J, Fakhry C, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Frank SJ, Nair SG, Bahig H, Ridge JA, Caudell J, Donaldson C, Clifford BT, Shenouda G, Birrer MJ, Chen Y, Le QT.
PMID: 34729846
Head Neck. 2022 Jan;44(1):158-167. doi: 10.1002/hed.26915. Epub 2021 Nov 03.

BACKGROUND: No risk-stratification strategies exist for patients with recurrent oropharyngeal cancer (OPC).METHODS: Retrospective analysis using data from prospective NRG Oncology clinical trials RTOG 0129 and 0522. Eligibility criteria included known p16 status and smoking history, and locoregional/distant recurrence. Overall...

Cite
Bigelow EO, Harris J, Fakhry C, et al. Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522. Head Neck. 2021;44(1):158-167doi: 10.1002/hed.26915.
Bigelow, E. O., Harris, J., Fakhry, C., Gillison, M. L., Nguyen-Tân, P. F., Rosenthal, D. I., Frank, S. J., Nair, S. G., Bahig, H., Ridge, J. A., Caudell, J., Donaldson, C., Clifford, B. T., Shenouda, G., Birrer, M. J., Chen, Y., & Le, Q. T. (2022). Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522. Head & neck, 44(1), 158-167. https://doi.org/10.1002/hed.26915
Bigelow, Elaine O, et al. "Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522." Head & neck vol. 44,1 (2022): 158-167. doi: https://doi.org/10.1002/hed.26915
Bigelow EO, Harris J, Fakhry C, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Frank SJ, Nair SG, Bahig H, Ridge JA, Caudell J, Donaldson C, Clifford BT, Shenouda G, Birrer MJ, Chen Y, Le QT. Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522. Head Neck. 2022 Jan;44(1):158-167. doi: 10.1002/hed.26915. Epub 2021 Nov 03. PMID: 34729846.
Copy Download .nbib Format: NLM
Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis.

Gynecologic oncology

Levinson K, Beavis AL, Purdy C, Rositch AF, Viswanathan A, Wolfson AH, Kelly MG, Tewari KS, McNally L, Guntupalli SR, Ragab O, Lee YC, Miller DS, Huh WK, Wilkinson KJ, Spirtos NM, Van Le L, Casablanca Y, Holman LL, Waggoner SE, Fader AN.
PMID: 34217544
Gynecol Oncol. 2021 Sep;162(3):532-538. doi: 10.1016/j.ygyno.2021.06.017. Epub 2021 Jul 01.

PURPOSE: The Sedlis criteria define risk factors for recurrence warranting post-hysterectomy radiation for early-stage cervical cancer; however, these factors were defined for squamous cell carcinoma (SCC) at an estimated recurrence risk of ≥30%. Our study evaluates and compares risk...

Cite
Levinson K, Beavis AL, Purdy C, et al. Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis. Gynecol Oncol. 2021;162(3):532-538doi: 10.1016/j.ygyno.2021.06.017.
Levinson, K., Beavis, A. L., Purdy, C., Rositch, A. F., Viswanathan, A., Wolfson, A. H., Kelly, M. G., Tewari, K. S., McNally, L., Guntupalli, S. R., Ragab, O., Lee, Y. C., Miller, D. S., Huh, W. K., Wilkinson, K. J., Spirtos, N. M., Van Le, L., Casablanca, Y., Holman, L. L., Waggoner, S. E., & Fader, A. N. (2021). Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis. Gynecologic oncology, 162(3), 532-538. https://doi.org/10.1016/j.ygyno.2021.06.017
Levinson, Kimberly, et al. "Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis." Gynecologic oncology vol. 162,3 (2021): 532-538. doi: https://doi.org/10.1016/j.ygyno.2021.06.017
Levinson K, Beavis AL, Purdy C, Rositch AF, Viswanathan A, Wolfson AH, Kelly MG, Tewari KS, McNally L, Guntupalli SR, Ragab O, Lee YC, Miller DS, Huh WK, Wilkinson KJ, Spirtos NM, Van Le L, Casablanca Y, Holman LL, Waggoner SE, Fader AN. Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis. Gynecol Oncol. 2021 Sep;162(3):532-538. doi: 10.1016/j.ygyno.2021.06.017. Epub 2021 Jul 01. PMID: 34217544; PMCID: PMC8405564.
Copy Download .nbib Format: NLM
An Overview of Phase 2 Clinical Trial Designs.

International journal of radiation oncology, biology, physics

Torres-Saavedra PA, Winter KA.
PMID: 34363901
Int J Radiat Oncol Biol Phys. 2022 Jan 01;112(1):22-29. doi: 10.1016/j.ijrobp.2021.07.1700. Epub 2021 Aug 04.

Clinical trials are studies to test new treatments in humans. Typically, these treatments are evaluated over several phases to assess their safety and efficacy. Phase 1 trials are designed to evaluate the safety and tolerability of a new treatment,...

Cite
Torres-Saavedra PA, Winter KA. An Overview of Phase 2 Clinical Trial Designs. Int J Radiat Oncol Biol Phys. 2021;112(1):22-29doi: 10.1016/j.ijrobp.2021.07.1700.
Torres-Saavedra, P. A., & Winter, K. A. (2022). An Overview of Phase 2 Clinical Trial Designs. International journal of radiation oncology, biology, physics, 112(1), 22-29. https://doi.org/10.1016/j.ijrobp.2021.07.1700
Torres-Saavedra, Pedro A, and Winter, Kathryn A. "An Overview of Phase 2 Clinical Trial Designs." International journal of radiation oncology, biology, physics vol. 112,1 (2022): 22-29. doi: https://doi.org/10.1016/j.ijrobp.2021.07.1700
Torres-Saavedra PA, Winter KA. An Overview of Phase 2 Clinical Trial Designs. Int J Radiat Oncol Biol Phys. 2022 Jan 01;112(1):22-29. doi: 10.1016/j.ijrobp.2021.07.1700. Epub 2021 Aug 04. PMID: 34363901.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 103 entries